544 Characterization of Potent and Well Tolerated Second Generation FLT3 Inhibitors
Marina Ciomei(Nerviano Medical Sciences), Andrea Borgia(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Enrico Pesenti, Ivan Fraietta, Sabrina Cribioli(Nerviano Medical Sciences), G. Texido Romero, Nadia Amboldi(University of Pavia), Arturo Galvani(Nerviano Medical Sciences), Christopher Nuccio
Cited by 0
Related Papers
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
|Molecular Cancer Therapeutics|2017|93